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LETTERS TO THE EDITOR
Percutaneous Laser Revascularization in
Patients With Chronic Total Occlusions
As clinical investigators of the percutaneous myocardial revascu-
larization (PMR) device, we read with interest “A Prospective,
Multicenter, Randomized Trial of Percutaneous Transmyocardial
Laser Revascularization in Patients With Nonrecanalizable
Chronic Total Occlusions” (PMR-CTO trial) by Stone and
colleagues (1). Based upon the lack of available follow-up data and
objective evidence, we do not agree with their negative conclusions
regarding this study or with their generalizations regarding differ-
ent laser systems.
There was approximately 50% available follow-up data for both
primary study end points at six months: namely total exercise
duration and angina improvement. The limited six-month
follow-up data favors PMR-treated patients and may have
achieved significance with complete follow-up at 6 and 12 months.
Importantly, the review of major adverse events through six
months supports the reasonable safety of the procedure.
The discussion regarding laser technology, along with the
conclusion of the need for further study of PMR, leaves the
impression that the laser systems used in the various studies are
similar and presumes that the difference in trial outcomes is
explained by protocol design. Despite being HO:YAG systems,
the lasers used in the various studies discussed are not similar
regarding energy delivery and tissue interaction. The (DMR) laser
system used in the DIRECT study transmitted a single energy
pulse to the endocardial surface and did not advance into the
endocardium to create a channel. The DMR system was designed
for triggering an endogenous tissue response, not for channel
formation (2). The CardioGenesis PMR laser systems fiberoptics
deliver multiple energy pulses while penetrating into the myocar-
dium to create deep, non-transmural channels. Based on the
negative outcome for the DIRECT trial utilizing the DMR
system, it is clear that fiberoptic penetration into the myocardium
and significant channel formation, as with PMR, are essential to
achieving clinical benefit.
For PMR, the placebo question has been effectively addressed
by the independently conducted, randomized, double blind, true-
sham BELIEF trial, which was performed to assess the potential
of placebo as a principal mechanism for angina improvement with
the CardioGenesis Axcis PMR system. The investigators con-
cluded that the significant 12-month clinical benefit for PMR-
treated patients, compared to sham control, was not attributable to
placebo (3). During the BELIEF trial, patients, investigators, and
assessors were blinded, and cardiac medications were held con-
stant. In the PMR-CTO trial, physicians were not blinded, and
patient blinding (i.e., heavy sedation, PMR simulation, eye cov-
erage) may not have been consistently achieved. Whereas Stone
and Colleagues challenge the lack of increased exercise tolerance or
reduction in ischemia in BELIEF, the study was not designed or
intended to show a change in those measures. Studies performed
with the CardioGenesis PMR system, examining perfusion with
position emission tomography (PET), have shown significant
perfusion improvement (4,5).
Three randomized, multi-center trials [PACIFIC (6), PMR010
(7), and the independent BELIEF] encompassing nearly 650
patients have been completed with the CardioGenesis PMR
systems. All have consistently demonstrated a significant clinical
benefit favoring the PMR-treated patients in all primary end
points, with significantly improved functional capacity at 12
months. PMR is not DMR.
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REPLY
We agree with Perin et al. that a pressing clinical need exists for an
effective therapeutic approach for the large number of patients with
advanced coronary artery disease and no revascularization options
(1). However, given the potential risks and resource utilization of
laser myocardial revascularization, it is mandatory that its clinical
utility be definitively demonstrated in appropriately designed
randomized trials, especially as most studies have not shown a
reduction in inducible ischemia with this technique. In this regard,
few would question that blinding and placebo effect issues have
clouded the promising new field of laser myocardial revasculariza-
tion and have delayed the regulatory approval of this potentially
useful modality.
We attempted to address these issues with a multicenter,
randomized prospective trial of percutaneous myocardial revascu-
larization (PMR) incorporating blinding. Our trial revealed sig-
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